TIGAR and cervical carcinoma: These aggregate findings suggest that inhibiting TIGAR functions could potentially hypersensitize hrHPV-associated cervical cancer cells to DNA-damage and cytotoxicity induced by chemotherapeutic agents that cause oxidative stress, and may sensitize these tumor cells to cyclophosphamide-a phosphoramide DNA-alkylating drug that is not presently indicated for use against hrHPV+ cervical cancers and which Hela cells are known to have resistance to.